Literature DB >> 18635220

Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies.

Robert Abouassaly1, Nelly Tan, Ayman Moussa, J Stephen Jones.   

Abstract

PURPOSE: Prostatic glandular atypia is present in approximately 5% of traditional template biopsy specimens. Prior reports suggest this finding carries a 40% risk of prostate cancer on subsequent biopsy. We determined the risk of malignancy in patients with atypia diagnosed on saturation biopsy.
MATERIALS AND METHODS: We identified 57 patients with a diagnosis of atypia who underwent repeat biopsy between January 2001 and August 2007. Charts were reviewed for clinical and pathological information.
RESULTS: Median patient age was 62 years (range 46 to 79). Of the 57 patients 19 (33%) had atypia diagnosed on saturation biopsy (20 cores or greater) (group 1), whereas 38 (67%) had atypia diagnosed with a more traditional biopsy technique (12 cores or fewer) (group 2). All patients subsequently underwent saturation repeat biopsy a median of 5 months after the original biopsy. Eight group 1 patients (42%) were found to have cancer on rebiopsy compared to 15 (39.5%) in group 2 (p = 1.00). Whereas only 1 of the 8 patients (12.5%) with cancer in group 1 had a Gleason score of 7 or greater, this was found in 5 of the 15 (33%) in group 2 (p = 0.37). Interestingly patients with cancer were less likely to have inflammation on initial biopsy (p = 0.05).
CONCLUSIONS: The finding of atypia on prostate biopsy is associated with a high likelihood of underlying malignancy regardless of the number of cores taken on initial biopsy. Inflammation in the initial biopsy may create a false-positive finding of atypia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635220     DOI: 10.1016/j.juro.2008.05.019

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Prostate cancer: The optimal number and location of cores for repeat biopsy.

Authors:  J Stephen Jones
Journal:  Nat Rev Urol       Date:  2011-10-25       Impact factor: 14.432

Review 2.  Strategies for repeat prostate biopsies.

Authors:  Martha K Terris
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

3.  Impact of immediate TRUS rebiopsy in a patient cohort considering active surveillance for favorable risk prostate cancer.

Authors:  Andre C King; Andrew Livermore; Timo A J Laurila; Wei Huang; David F Jarrard
Journal:  Urol Oncol       Date:  2011-08-03       Impact factor: 3.498

4.  The impact of African American race on prostate cancer detection on repeat prostate biopsy in a veteran population.

Authors:  William A Sterling; Joseph Weiner; David Schreiber; Komal Mehta; Jeffrey P Weiss
Journal:  Int Urol Nephrol       Date:  2016-08-31       Impact factor: 2.370

Review 5.  Management of rising prostate-specific antigen after a negative biopsy.

Authors:  David A Levy; J Stephen Jones
Journal:  Curr Urol Rep       Date:  2011-06       Impact factor: 3.092

6.  Contemporary pathologic characteristics and oncologic outcomes of prostate cancers missed by 6- and 12-core biopsy and diagnosed with a 21-core biopsy protocol.

Authors:  Idir Ouzaid; Evanguelos Xylinas; Alexandre Campeggi; Andras Hoznek; Dimitri Vordos; Claude-Clément Abbou; Francis Vacherot; Laurent Salomon; Alexandre de la Taille; Guillaume Ploussard
Journal:  World J Urol       Date:  2011-11-25       Impact factor: 4.226

Review 7.  Single foci prostate cancer: current diagnosis and management.

Authors:  Ioannis Efthimiou; Konstadinos Skrepetis; Elefteria Bournia
Journal:  Curr Urol       Date:  2013-07-28

Review 8.  Atypical small acinar proliferation and its significance in pathological reports in modern urological times.

Authors:  Georgios Tsampoukas; Victor Manolas; Dominic Brown; Athanasios Dellis; Konstantinos Deliveliotis; Mohamad Moussa; Athanasios Papatsoris
Journal:  Asian J Urol       Date:  2021-04-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.